PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib
Oregon Health & Science University · Portland VA Medical Center
Abstract
We determined the KIT and PDGFRA mutation status of 1,105 unique GISTs using a combination of denaturing high-performance liquid chromatography and direct sequencing.
66 in exon 18, 11 in exon 12, and three in exon 14. Transient expression of representative PDGFRA isoforms in CHO cells revealed imatinib sensitivity of exon 12 mutations (SPDHE566-571R and insertion ER561-562) and an exon 14 substitution (N659K). However, most isoforms with a substitution involving codon D842 in exon 18 (D842V, RD841-842KI, DI842-843IM) were resistant to the drug, with the exception of D842Y. Interestingly, other mutations in exon 18 (D846Y, N848K, Y849K and HDSN845-848P) were all imatinib sensitive. Proliferation studies with BA/F3 cell lines stably expressing selected PDGFRA mutant isoforms supported these findings.
Citation impact
- FWCI
- 22.91
- Percentile
- 100%
- References
- 43
Authors
10- CLChristopher L. CorlessCorresponding
Oregon Health & Science University, Portland VA Medical Center
- ASArin Schroeder
Oregon Health & Science University, Portland VA Medical Center
- DGDiana Griffith
Oregon Health & Science University, Portland VA Medical Center
- ATAjia Town
Oregon Health & Science University, Portland VA Medical Center
- LMLaura McGreevey
Oregon Health & Science University, Portland VA Medical Center
Topics & keywords
- PDGFRA
- Imatinib
- Exon
- Cancer research
- Mutation
- GiST
- Tyrosine kinase
- Imatinib mesylate
- Good health and well-being